盡管實驗室和臨床癌癥研究需要緊密聯(lián)系，但在基礎(chǔ)水平的觀察常常被排除在醫(yī)學(xué)應(yīng)用之外。該期刊致力于加快實驗結(jié)果的臨床轉(zhuǎn)化，并再次回到實驗室進(jìn)行進(jìn)一步的研究。這項工作的根本目的是提高對癌癥的臨床相關(guān)知識，提高對惡性疾病的預(yù)防、診斷和治療的結(jié)果。該雜志發(fā)表了來自世界各地癌癥項目的重要臨床研究，以及重要的轉(zhuǎn)化實驗室發(fā)現(xiàn)、微型評論(邀請并提交)和深入討論腫瘤學(xué)領(lǐng)域不斷發(fā)展和有爭議的話題。雜志的一個獨特的特性是一個專注于快速的部分同行評議和隨后出版短篇報告階段1和階段2的癌癥臨床試驗,確保高質(zhì)量的臨床癌癥研究的目標(biāo)迅速進(jìn)入公共領(lǐng)域,無論關(guān)于功效和毒性試驗的最終結(jié)論。

Although laboratory and clinical cancer research need to be closely linked, ob?servations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.